undamentalytics Newsletter
Sign in

Sonoma Pharmaceuticals, Inc. revenue

Sonoma Pharmaceuticals, Inc.'s revenue was $19.5m in fiscal 2026, up 36.7% on the year before. Since fiscal 2011 ($9.8m) it has grown at a compound 4.7% a year. Over the last twelve months it was $21.9m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Mar 20112012Mar 20122013Mar 20132014Mar 20142015Mar 20152016Mar 20162017Mar 20172018Mar 20182019Mar 20192020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Revenue101315141491317191819131313142022
Growth on the year before—+30.7%+21.2%−11.5%+1.4%−32.4%+36.9%+29.9%+13.9%−5.5%+3.9%−32.2%+5.1%−4.0%+12.2%+36.7%—
Gross profit691187367987445579

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Sonoma Pharmaceuticals, Inc. $21.9m 47.0% 19.9%
Baird Medical Investment Holdings Ltd $22.5m -39.2% —
Vivos Therapeutics, Inc. $20.9m 45.2% 10.6%
Nephros Inc $20.7m 24.2% 19.3%
Jin Medical International Ltd. $20.7m -12.0% —
QT Imaging Holdings, Inc. $26.4m 220.0% —

Compare with peers

Head to head: BDMD vs SNOASNOA vs VVOSNEPH vs SNOASNOA vs ZJYL

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Sonoma Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sonoma Pharmaceuticals, Inc.